Overcoming Pre-existing Anti-AAV Neutralizing Antibodies

Time: 1:30 pm
day: Day Two


  • Pre-existing anti-AAV neutralizing antibodies (NAbs) preclude some patients from receiving systemic AAV gene therapy
  • Vector readministration is also currently impossible in patients who only realize suboptimal transgene expression due to high NAb from the first vector administration
  • Emerging strategies that reduce or eliminate NAbs can increase patients treated with AAV while allowing vector readministration